Pdcd4 Repression of Lysyl Oxidase Inhibits Hypoxia-induced Breast Cancer Cell Invasion

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2010 May 26

PMID 20498644

Citations 41

Authors

A N Santhanam

A R Baker

G Hegamyer

D A Kirschmann

N H Colburn

Affiliations

Soon will be listed here.

Abstract

Metastasis to bone, liver and lungs is the primary cause of death in breast cancer patients. Our studies have revealed that the novel tumor suppressor Pdcd4 inhibits breast cancer cell migration and invasion in vitro. Loss of Pdcd4 in human nonmetastatic breast cancer cells increased the expression of lysyl oxidase (LOX) mRNA. LOX is a hypoxia-inducible amine oxidase, the activity of which enhances breast cancer cell invasion in vitro and in vivo. Specific inhibition of LOX activity by beta-aminopropionitrile or small interfering RNA decreased the invasiveness of T47D and MCF7 breast cancer cells attenuated for Pdcd4 function. Most significantly, loss of Pdcd4 augments hypoxia induction of LOX as well. Conversely, overexpression of Pdcd4 significantly reversed the hypoxia induction of LOX expression in T47D cells attenuated for Pdcd4. However, Pdcd4 did not affect hypoxia-inducible factor-1 (HIF-1) protein expression or HIF-1-responsive element-luciferase activity in response to hypoxia, suggesting that Pdcd4 regulation of LOX occurs through an HIF-independent mechanism. Nevertheless, the loss of Pdcd4 early in cancer progression may have an important role in the increased sensitivity of cancer cells to hypoxia through increased LOX activity and concomitant enhanced invasiveness.

Citing Articles

The Impact of Pdcd4, a Translation Inhibitor, on Drug Resistance.

Wang Q, Yang H Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459035 PMC: 11510623. DOI: 10.3390/ph17101396.

Lysyl Oxidase (LOX) Family Proteins: Key Players in Breast Cancer Occurrence and Progression.

Li J, Wang X, Liu R, Zi J, Li Y, Li Z J Cancer. 2024; 15(16):5230-5243.

PMID: 39247609 PMC: 11375560. DOI: 10.7150/jca.98688.

PDCD4 triggers α-synuclein accumulation and motor deficits via co-suppressing TFE3 and TFEB translation in a model of Parkinson's disease.

Cao B, Chen X, Li Y, Zhou T, Chen N, Guo Y NPJ Parkinsons Dis. 2024; 10(1):146.

PMID: 39107320 PMC: 11303393. DOI: 10.1038/s41531-024-00760-9.

MicroRNA-183 cluster: a promising biomarker and therapeutic target in gastrointestinal malignancies.

Zheng Y, Sukocheva O, Tse E, Neganova M, Aleksandrova Y, Zhao R Am J Cancer Res. 2024; 13(12):6147-6175.

PMID: 38187051 PMC: 10767355.

Role of the Hypoxic-Secretome in Seed and Soil Metastatic Preparation.

Clemente-Gonzalez C, Carnero A Cancers (Basel). 2022; 14(23).

PMID: 36497411 PMC: 9738438. DOI: 10.3390/cancers14235930.

References

Kagan H, Li W . Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem. 2003; 88(4):660-72. DOI: 10.1002/jcb.10413. View

Li Y, Zhou B, Deng J, Pan Y, Hay N, Hung M . A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res. 2005; 65(8):3257-63. DOI: 10.1158/0008-5472.CAN-04-1284. View

Ivan M, Harris A, Martelli F, Kulshreshtha R . Hypoxia response and microRNAs: no longer two separate worlds. J Cell Mol Med. 2008; 12(5A):1426-31. PMC: 3918058. DOI: 10.1111/j.1582-4934.2008.00398.x. View

Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo Y . MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008; 18(3):350-9. DOI: 10.1038/cr.2008.24. View

Kulshreshtha R, Ferracin M, E Wojcik S, Garzon R, Alder H, Agosto-Perez F . A microRNA signature of hypoxia. Mol Cell Biol. 2006; 27(5):1859-67. PMC: 1820461. DOI: 10.1128/MCB.01395-06. View

Tan R, Taniguchi T, Harada H . Identification of the lysyl oxidase gene as target of the antioncogenic transcription factor, IRF-1, and its possible role in tumor suppression. Cancer Res. 1996; 56(10):2417-21. View

Kronblad A, Jirstrom K, Ryden L, Nordenskjold B, Landberg G . Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int J Cancer. 2005; 118(10):2609-16. DOI: 10.1002/ijc.21676. View

Bedogni B, Welford S, Cassarino D, Nickoloff B, Giaccia A, Powell M . The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell. 2005; 8(6):443-54. DOI: 10.1016/j.ccr.2005.11.005. View

Denko N, Fontana L, Hudson K, Sutphin P, Raychaudhuri S, Altman R . Investigating hypoxic tumor physiology through gene expression patterns. Oncogene. 2003; 22(37):5907-14. DOI: 10.1038/sj.onc.1206703. View

10.

Arsham A, Plas D, Thompson C, Simon M . Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis. Cancer Res. 2004; 64(10):3500-7. DOI: 10.1158/0008-5472.CAN-03-2239. View

11.

Payne S, Fogelgren B, Hess A, Seftor E, Wiley E, Fong S . Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res. 2005; 65(24):11429-36. DOI: 10.1158/0008-5472.CAN-05-1274. View

12.

Cmarik J, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H . Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci U S A. 1999; 96(24):14037-42. PMC: 24186. DOI: 10.1073/pnas.96.24.14037. View

13.

Bitomsky N, Bohm M, Klempnauer K . Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun. Oncogene. 2004; 23(45):7484-93. DOI: 10.1038/sj.onc.1208064. View

14.

Mudduluru G, Medved F, Grobholz R, Jost C, Gruber A, Leupold J . Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer. 2007; 110(8):1697-707. DOI: 10.1002/cncr.22983. View

15.

Goke R, Barth P, Schmidt A, Samans B, Lankat-Buttgereit B . Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). Am J Physiol Cell Physiol. 2004; 287(6):C1541-6. DOI: 10.1152/ajpcell.00025.2004. View

16.

Dorrello N, Peschiaroli A, Guardavaccaro D, Colburn N, Sherman N, Pagano M . S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science. 2006; 314(5798):467-71. DOI: 10.1126/science.1130276. View

17.

Kagan H . Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol. 1998; 16(7):387-98. DOI: 10.1016/s0945-053x(98)90012-9. View

18.

Chen H, Su W, Lin P, Guo H, Lee W . Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Res Treat. 2006; 103(2):167-75. DOI: 10.1007/s10549-006-9360-3. View

19.

Postovit L, Abbott D, Payne S, Wheaton W, Margaryan N, Sullivan R . Hypoxia/reoxygenation: a dynamic regulator of lysyl oxidase-facilitated breast cancer migration. J Cell Biochem. 2007; 103(5):1369-78. DOI: 10.1002/jcb.21517. View

20.

Kang Y . Functional genomic analysis of cancer metastasis: biologic insights and clinical implications. Expert Rev Mol Diagn. 2005; 5(3):385-95. DOI: 10.1586/14737159.5.3.385. View